沙库巴曲缬沙坦钠联合酒石酸美托洛尔片治疗冠心病伴慢性心力衰竭患者的效果  

Effects of Sacubitril Valsartan sodium combined with Metoprolol tartrate tablets in treatment of patients with coronary heart disease and chronic heart failure

作　　者：周增兴 ZHOU Zengxing(Department of Cardiology of Wanzai County People’s Hospital,Yichun 336100 Jiangxi,China)

机构地区：[1]万载县人民医院心内科,江西宜春336100

出　　处：《中国民康医学》2024年第23期18-20,34,共4页Medical Journal of Chinese People’s Health

摘　　要：目的:观察沙库巴曲缬沙坦钠联合酒石酸美托洛尔片治疗冠心病伴慢性心力衰竭(CHF)患者的效果。方法:选取2022年1月至2024年1月该院收治的60例冠心病伴CHF患者进行前瞻性研究,按随机数字表法将其分为观察组与对照组各30例。对照组予以酒石酸美托洛尔治疗,观察组在对照组基础上联合沙库巴曲缬沙坦钠治疗。比较两组临床疗效,治疗前后心功能指标[左心室射血分数(LVEF)、左心室舒张末期容积(LVEDV)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室收缩末期容积(LVESV)]、疾病相关指标[内皮素1(ET-1)、一氧化氮(NO)、N末端B型脑钠肽前体(NT-proBNP)]、炎性因子[白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、超敏C反应蛋白(hs-CRP)]水平,以及不良反应发生率。结果:观察组治疗总有效率为93.33%(28/30),高于对照组的73.33%(22/30),差异有统计学意义(P<0.05);治疗后,两组LVEF水平均高于治疗前,且观察组高于对照组,两组LVEDD、LVESD、LVEDV、LVESV水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组ET-1、NTproBNP水平均低于治疗前,且观察组低于对照组,两组NO水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组IL-6、IL-8、hs-CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗期间,两组均未发生明显不良反应。结论:沙库巴曲缬沙坦钠联合酒石酸美托洛尔治疗冠心病伴CHF患者可提高治疗总有效率,改善心功能指标和疾病相关指标水平,以及降低炎性因子水平,效果优于单纯酒石酸美托洛尔治疗。Objective:To observe effects of Sacubitril Valsartan sodium combined with Metoprolol tartrate tablets in treatment of patients with coronary heart disease and chronic heart failure(CHF).Methods:A prospective study was conducted on 60 patients with coronary heart disease and CHF admitted to the hospital from January 2022 to January 2024.According to the random number table method,they were divided into observation group and control group,30 cases in each group.The control group was treated with Metoprolol tartrate,while the observation group was treated with Sacubitril Valsartan sodium on the basis of that of the control group.The clinical efficacy,the levels of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic volume(LVEDV),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular end-systolic volume(LVESV)],disease-related indexes[endothelin-1(ET-1),nitric oxide(NO),N-terminal B-type brain natriuretic peptide precursor(NT-proBNP)]and inflammatory factors[interleukin-6(IL-6),interleukin-8(IL-8),high sensitivity C-reactive protein(hs-CRP)],and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 93.33%(28/30),which was higher than 73.33%(22/30)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the LVEF levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of LVEDD,LVESD,LVEDV and LVESV in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of ET-1 and NT-proBNP in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the contro

关 键 词：冠心病 慢性心力衰竭 沙库巴曲缬沙坦钠片 酒石酸美托洛尔片 心功能 炎性因子 不良反应 

分 类 号：R541.6[医药卫生—心血管疾病]